Could a single infusion of COVID-Fighting antibodies keep High-Risk patients out of the hospital?
NCT ID NCT04910269
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study tests whether a single infusion of hyperimmune immunoglobulin (hIVIG) — concentrated antibodies from recovered COVID-19 patients — can help adults at high risk (age 55+ or with weakened immune systems) who have early COVID-19. Participants receive either the antibody infusion or a placebo (salt water) and are followed for 28 days to see if they recover faster or avoid hospitalization. The trial was suspended, so results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
3rd Dept of Medicine, Medical School
Athens, Attica, 11527, Greece
-
4th Department of Internal Medicine
Athens, Attica, 12462, Greece
-
Aarhus Universitetshospital, Skejby
Aarhus, N, 8200, Denmark
-
Bamrasnaradura Infections Diseases Institute (613-007)
Nonthaburi, 11000, Thailand
-
Bispebjerg Hospital
Copenhagen, 2400, Denmark
-
CAP Can Bou
Castelldefels, Barcelona, 08860, Spain
-
CAP Corbera
Barcelona, 08757, Spain
-
CAP El Maresme
Mataró, Barcelona, 08303, Spain
-
CHRISTUS Spohn Shoreline Hospital
Corpus Christi, Texas, 78404, United States
-
Carilion Medical Center (Site 080-018)
Roanoke, Virginia, 24015, United States
-
Central City Clinical Hospital of Ivano-Frankivsk City Council
Ivano-Frankivsk, 76018, Ukraine
-
Centro de Investigaciones Medicas de Mar del Plata (Site 611-031)
Mar del Plata, Buenos Aires, B7600FYK, Argentina
-
Chulalongkorn University and The HIV-NAT
Pathum Wan, Bangkok, 10330, Thailand
-
Cleveland Clinic Foundation (Site 207-001)
Cleveland, Ohio, 44195, United States
-
Clínica Central S.A. (611-028)
Villa Regina, Río Negro Province, R8336, Argentina
-
Department of Clinical Therapeutics of Alexandra Hospital
Athens, Attica, 11528, Greece
-
Department of Infectious Diseases
Aalborg, 9000, Denmark
-
Dept of Critical Care and Pulmonary Medicine, Evangelismos General Hospital
Athens, Attica, 10676, Greece
-
Henry Ford Health System Site (014-001)
Detroit, Michigan, 48202, United States
-
Herlev/Gentofte Hospital
Hellerup, 2900, Denmark
-
Hospital General Dr. Aurelio Valdivieso
Oaxaca City, OA, 68050, Mexico
-
Hospital General Dr. Manuel Gea Gonzáles
Mexico City, Mexico City, 14080, Mexico
-
Hospital General de Agudos JM Ramos Mejia
Buenos Aires, C1221ADC, Argentina
-
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
Hvidovre University Hospital, Department of Infectious Diseases
Hvidovre, 2650, Denmark
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Instituto Medico Platense
La Plata, Buenos Aires, B1900AVG, Argentina
-
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico City, 14080, Mexico
-
Instituto Nacional de Enfermedades Respiratorias Ismael Cosió Villegas
Mexico City, Mexico City, 14080, Mexico
-
Intermountain Medical Center (211-001)
Murray, Utah, 84107, United States
-
Joint Clinical Research Center (JCRC)
Kampala, Uganda
-
Khon Kaen University, Srinagarind Hospital (Site 613-003)
Khon Kaen, 40002, Thailand
-
Kolding Sygehus
Kolding, 6000, Denmark
-
Laiko Athens General Hospital
Athens, Attica, 11527, Greece
-
Lira Regional Referral Hospital
Lira, Uganda
-
MRC/UVRI & LSHTM Uganda Research Unit
Entebbe, Uganda
-
Makerere University Lung Institute (Site 634-604)
Kampala, Uganda
-
Masaka Regional Referral Hospital
Masaka, Uganda
-
Odense University Hospital
Odense, C, 5000, Denmark
-
Penn State Health Milton S. Hershey Medical Center (209-002)
Hershey, Pennsylvania, 17033, United States
-
Rigshospitalet, CHIP
Copenhagen, 2100, Denmark
-
Rocky Mountain Regional VA Medical Center (074-010)
Aurora, Colorado, 80045, United States
-
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
Salem VA Medical Center (074-014)
Salem, Virginia, 24153, United States
-
San Francisco VAMC (Site 074-002)
San Francisco, California, 94121, United States
-
Siriraj Hospital (Site 613-002)
Bangkok Noi, Bangkok, 10700, Thailand
-
Southern Arizona VA Healthcare System (074-009)
Tucson, Arizona, 85723, United States
-
St. Francis Hospital, Nsambya
Kampala, Uganda
-
St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
Stanford University Hospital & Clinics (Site 203-003)
Palo Alto, California, 94305, United States
-
Swedish Hospital First Hill
Seattle, Washington, 98122, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
UVA Health System, University Hospital (Site 210-003)
Charlottesville, Virginia, 22908, United States
-
Unidad de Ensayos Clinicos Socios En Salud Sucursal Perú (651-009)
Lima, 15012, Peru
-
University College London Hospitals
London, WC1E 6JB, United Kingdom
-
University Malaya Medical Centre (Site 612-501)
Kuala Lumpur, Kuala Lumpur, 59100, Malaysia
-
VA Northern California Health Care System (074-023)
Mather, California, 95655, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG)
What this could lead to
If it works, this could provide a new treatment option for early COVID-19 in high-risk outpatients, reducing severe illness and hospital stays.
What could go wrong
This trial is suspended, so results are unknown. The treatment may not improve outcomes over placebo, and risks like infusion reactions or lack of benefit are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.